阿斯利康中国宣布组织架构调整和人事变动,聚焦呼吸与自体免疫、疫苗及免疫疗法两大领域。新设两大事业部,并有多项人事任命和离职。此举与公司产品管线进展密切相关,计划至2030年在中国引入至少20款创新药物。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.